Omapatrilat: Still a promise in salt-sensitive hypertension?

Journal of Hypertension

Volumn 21, Issue 1, 2003, Pages 31-32

  Tojo, Akihiro ^a   Fujita, Toshiro ^a   Wilcox, Christopher S ^b  

^a UNIVERSITY OF TOKYO   (Japan)

^b GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; BRADYKININ; DEOXYCORTICOSTERONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FASIDOTRIL; GEMOPATRILAT; LISINOPRIL; MEMBRANE METALLOENDOPEPTIDASE; OMAPATRILAT; SAMPATRILAT; UNCLASSIFIED DRUG;

ANGIONEUROTIC EDEMA; ANIMAL CELL; ANIMAL TISSUE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG INDICATION; DRUG MECHANISM; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERTENSION; MULTICENTER STUDY; NONHUMAN; NOTE; PRIORITY JOURNAL; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL; RAT; RISK BENEFIT ANALYSIS; SALT INTAKE; SMOKING; SURVIVAL; THROMBOCYTE AGGREGATION; VASOSPASM;

EID: 0037252063     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-200301000-00008     Document Type: Note

References (7)

1. Weber M. Vasopeptidase inhibitors. Lancet 2001; 358:1525-1532.
2. Ferrario CM, Smith RD, Brosnihen B, Chappell MC, Campese VM, Vesterqvist O, et al. Effects of omapatrilat on the renin-angiotensin system in salt-sensitive hypertension. Am J Hypertens 2002; 15:557-564.
3. Millette E, Demeilliers B, Wu R, Laplante MA, Midaoui AE, Moreau P, et al. Comparison of the cardiovascular protection by omapatrilat and lisinopril treatments in DOCA-salt hypertension. J Hypertens 2003; 21:125-135.
4. Coats AJS. Omapatrilat - the story of overture and octave. Int J Cardiol 2002; 86:1-4.
5. Armstrong PW, Lorell BH, Nissen S, Borer J. Omapatrilat. Circulation 2002; 106:9011E-9012E.
6. Trippodo NC, Fox M, Monticelo TM, Panchal BC, Asaad MM. Vasopeptidase inhibition with omapatrilat improves cardiac geometry and survival in cardiomyopathic hamsters more than does ACE inhibition with captopril. J Cardiovasc Pharmacol 1999; 34:782-790.
7. Rouleau JL, Pfeffer MA, Stewart DJ, Isaac D, Sestier F, Kerut EK, et al. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomized trial. Lancet 2000; 356:615-620.